Sarepta settles REGENXBIO, UPenn patent litigation for USD 39 million

By Public Technologies
  • Sarepta Therapeutics reached a settlement on Sept. 23, 2026 to resolve patent infringement litigation tied to AAVrh74-based gene therapies.
  • Payment of USD 39 million due to REGENXBIO within 10 days; charge previously recorded for the quarter ended June 30, 2026.
  • REGENXBIO and the University of Pennsylvania released claims through the effective date tied to certain AAVrh74-related patents.
  • Non-suit commitments cover ELEVIDYS and other AAVrh74-based programs; REGENXBIO also agreed not to sue over patents covering existing ELEVIDYS.
  • Cases to be dismissed with prejudice; no admission of liability; each party to cover its own legal costs.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sarepta Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-399416), on September 23, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.